Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Ukihide Tateishi"'
Autor:
Koji Hatano, Fumihiko Soeda, Frederik L. Giesel, Hidetaka Sasaki, Takeshi Ujike, Eku Shimosegawa, Jens Cardinale, Takashi Kamiya, Motohide Uemura, Hiroki Kato, Norio Nonomura, Sadahiro Naka, Tadashi Watabe, Ukihide Tateishi
Publikováno v:
Annals of Nuclear Medicine
Objective 18F-labeled prostate-specific membrane antigen (PSMA) ligand, [18F]PSMA-1007, has the benefit of a higher synthetic yield and minimal excretion in the urine. High detection efficacy was reported in biochemical recurrence (BCR) of prostate c
Autor:
Marie Takahashi, Junichi Tsuchiya, Kota Yokoyama, Masato Tominaga, Makiko Honda, Ukihide Tateishi, Mirai Kawano, Hyeyeol Bae, Koichiro Kimura
Publikováno v:
Annals of Nuclear Medicine. 35:580-588
NMB58 is a novel positron emission tomography (PET) tracer containing flurpiridaz as an active ingredient and available as a myocardial perfusion imaging tracer that targets mitochondrial complex 1. A phase I clinical study of NMB58 was conducted to
Publikováno v:
Cancer Imaging, Vol 20, Iss 1, Pp 1-7 (2020)
Cancer Imaging
Cancer Imaging
Background To document 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) findings after percutaneous cryoablation for early breast cancer. Methods Data of 193 consecutive patients who had undergone cryoablation for inva
Autor:
Ukihide Tateishi
Publikováno v:
Japanese Journal of Clinical Oncology
From a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for both diagnosis and radioligand therapy (RLT) of prostate cancer. The term ‘specific’ has been used to characterize a histologic hallmark of overexpres
Autor:
Atsushi, Kudo, Ukihide, Tateishi, Ryoichi, Yoshimura, Junichi, Tsuchiya, Kota, Yokoyama, Shoko, Takano, Noritoshi, Kobayashi, Daisuke, Utsunomiya, Masaharu, Hata, Yasushi, Ichikawa, Minoru, Tanabe, Makoto, Hosono, Seigo, Kinuya
Publikováno v:
Journal of hepato-biliary-pancreatic sciencesREFERENCES. 29(4)
The present prospective phase 1/2 study aimed to elucidate the efficacy and safety ofFrom April 2018 to October 2020, 15 patients with advanced NETs (five midgut, eight pancreatic, and two lung NETs) were enrolled. Objective response rate (ORR), prog
Publikováno v:
Japanese journal of radiology. 39(3)
Improvements in positron emission tomography (PET) technology have contributed to increased diagnostic accuracy in patients with large-vessel vasculitis (LVV) over the last decades. Many systematic reviews and meta-analyses were conducted, and earlie
Autor:
Ukihide Tateishi, Toshiki Terao, Rikako Tabata, Kentaro Narita, Ayumi Kuzume, Daisuke Miura, Masami Takeuchi, Kosei Matsue, Takafumi Tsushima, Youichi Machida
Publikováno v:
European radiology. 31(8)
This study compared the tumor burden and prognostic impact of total diffusion volume (tDV) and total lesion glycolysis (TLG) in the same patients with newly diagnosed multiple myeloma (NDMM) simultaneously. We also examined the relationship between t
Autor:
Koichiro, Kimura, Junichi, Tsuchiya, Osamu, Manabe, Kota, Yokoyama, Ishikawa, Toshiaki, Ukihide, Tateishi
Publikováno v:
European journal of nuclear medicine and molecular imaging. 48(3)
Autor:
Kota, Yokoyama, Osamu, Manabe, Jyunichi, Tsuchiya, Jun, Oyama, Hiroaki, Kawabe, Yumiko, Tateishi, Takahiro, Asakage, Kouhei, Yamamoto, Ukihide, Tateishi
Publikováno v:
European journal of nuclear medicine and molecular imaging. 48(4)
Autor:
Tomohiro Kaneta, Masahiro Yao, Ichiro Ikeda, Ryogo Minamimoto, Kazuhiro Namura, Ukihide Tateishi, Takashi Kawahara, Noboru Nakaigawa, Kazuki Kobayashi, Hiroji Uemura, Narihiko Hayashi, Daiki Ueno, Hisashi Hasumi, Jun-ichi Teranishi, Takeshi Kishida, Kentaro Muraoka, Yasuhide Miyoshi, Tomio Inoue, Kazuhide Makiyama, Koji Izumi, Keiichi Kondo, Yasushi Yumura, Kimito Osaka
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:739-744
We investigated prospectively whether 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) can predict the overall survival (OS) of patients with advanced renal cell carcinoma (RCC) previously treated by molecular